Free Trial
→ Dollar Collapse Warning: Protect Your Wealth NOW (From Lear Capital) (Ad) Buy GMTX Stock  Free GMTX Stock Alerts

Gemini Therapeutics (GMTX) Financials

Gemini Therapeutics logo
$47.37 -0.67 (-1.39%)
As of 05/23/2025
Compare
Annual Income Statements for Gemini Therapeutics

Annual Income Statements for Gemini Therapeutics

This table shows Gemini Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Income / (Loss) Attributable to Common Shareholders		 -109 -76 -47 -36 -41
Consolidated Net Income / (Loss)		 -109 -76 -47 -36 -41
Net Income / (Loss) Continuing Operations		 -109 -76 -47 -36 -41
Total Pre-Tax Income 		-109 -76 -47 -36 -41
Total Operating Income		 -130 -91 -47 -31 -34
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 130 91 47 31 34
Selling, General & Admin Expense		 33 22 14 5.76 5.87
Research & Development Expense		 97 69 33 25 28
Total Other Income / (Expense), net		 21 15 0.65 -5.04 -6.80
Interest Expense		 0.57 - - - 6.83
Interest & Investment Income		 21 15 0.71 0.01 0.04
Income Tax Expense		 0.36 0.10 0.00 - -
Other Gains / (Losses), net		 -0.00 - - - -
Basic Earnings per Share		 ($3.96) ($3.42) ($45.05) ($40.95) ($2.70)
Weighted Average Basic Shares Outstanding		 27.61M 22.32M 1.04M 878.41K 15.12M
Diluted Earnings per Share		 ($3.96) ($3.42) ($45.05) ($40.95) ($2.70)
Weighted Average Diluted Shares Outstanding		 27.61M 22.32M 1.04M 878.41K 15.12M
Weighted Average Basic & Diluted Shares Outstanding		 34.57M 24.68M 19.00M 40.36M 15.12M

Quarterly Income Statements for Gemini Therapeutics

This table shows Gemini Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 0.00 -29 -27 -26 -27 -24 -14 -16 -23 -11 -16
Consolidated Net Income / (Loss)		 -34 -29 -27 -26 -27 -24 -14 -16 -23 -11 -16
Net Income / (Loss) Continuing Operations		 -34 -29 -27 -26 -27 -24 -14 -16 -23 -11 -16
Total Pre-Tax Income 		-34 -29 -26 -26 -27 -24 -14 -16 -23 -11 -16
Total Operating Income		 -40 -35 -33 -31 -31 -30 -19 -17 -25 -15 -10
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 40 35 33 31 31 30 19 17 25 15 10
Selling, General & Admin Expense		 12 9.75 8.17 7.37 7.76 7.15 4.54 5.23 4.95 5.01 2.59
Research & Development Expense		 28 25 25 23 24 23 14 12 20 10 7.89
Total Other Income / (Expense), net		 5.98 5.27 6.37 4.56 4.52 6.17 4.86 1.41 2.37 3.78 -5.67
Interest Expense		 0.90 - - - - - - - - - -
Interest & Investment Income		 6.88 5.84 6.36 4.57 4.52 4.68 4.84 2.91 2.37 0.39 0.27
Other Income / (Expense), net		 -0.00 - 0.01 -0.01 -0.00 1.49 0.01 -1.51 0.00 3.39 -5.94
Income Tax Expense		 0.12 0.18 0.11 0.06 0.01 0.03 0.02 0.02 0.02 - 0.00
Basic Earnings per Share		 ($1.02) ($1.07) ($0.89) ($1.03) ($1.09) ($1.06) ($0.58) ($0.74) ($1.20) ($10.82) ($16.82)
Weighted Average Basic Shares Outstanding		 33.32M 27.61M 29.94M 25.65M 24.81M 22.32M 24.32M 21.48M 18.95M 1.04M 960.32K
Diluted Earnings per Share		 ($1.02) ($1.07) ($0.89) ($1.03) ($1.09) ($1.06) ($0.58) ($0.74) ($1.20) ($10.82) ($16.82)
Weighted Average Diluted Shares Outstanding		 33.32M 27.61M 29.94M 25.65M 24.81M 22.32M 24.32M 21.48M 18.95M 1.04M 960.32K
Weighted Average Basic & Diluted Shares Outstanding		 34.63M 34.57M 29.76M 29.73M 24.72M 24.68M 24.14M 22.88M 19.80M 19.00M 43.33M

Annual Cash Flow Statements for Gemini Therapeutics

This table details how cash moves in and out of Gemini Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Change in Cash & Equivalents		 -168 166 107 62 0.45
Net Cash From Operating Activities		 -94 -73 -42 -28 -33
Net Cash From Continuing Operating Activities		 -94 -73 -42 -28 -34
Net Income / (Loss) Continuing Operations		 -109 -76 -47 -36 -41
Consolidated Net Income / (Loss)		 -109 -76 -47 -36 -41
Depreciation Expense		 0.16 0.10 0.09 0.03 0.32
Amortization Expense		 -5.30 0.00 - - -
Non-Cash Adjustments To Reconcile Net Income		 22 5.94 2.04 6.98 7.47
Changes in Operating Assets and Liabilities, net		 -1.43 -3.07 2.44 1.43 -0.73
Net Cash From Investing Activities		 -292 -0.09 -0.15 -0.07 -0.02
Net Cash From Continuing Investing Activities		 -292 -0.09 -0.15 -0.07 -0.02
Purchase of Property, Plant & Equipment		 -0.51 -0.09 -0.15 -0.07 -0.02
Purchase of Investments		 -387 0.00 - - -
Sale and/or Maturity of Investments		 95 0.00 - - -
Net Cash From Financing Activities		 218 239 149 90 34
Net Cash From Continuing Financing Activities		 218 239 149 90 34
Repayment of Debt		 -1.39 0.00 0.00 0.00 0.00
Issuance of Debt		 29 0.00 0.00 0.00 14
Issuance of Common Equity		 188 199 54 0.00 20
Other Financing Activities, net		 2.98 40 95 0.07 0.16
Cash Interest Paid		 0.20 0.00 0.00 0.00 0.35
Cash Income Taxes Paid		 0.30 0.11 0.00 0.00 -

Quarterly Cash Flow Statements for Gemini Therapeutics

This table details how cash moves in and out of Gemini Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -70 -0.20 -88 -62 -18 -10 -7.06 141 42 139 -9.69
Net Cash From Operating Activities		 -41 -28 -17 -15 -34 -18 -7.48 -13 -35 -9.67 -9.69
Net Cash From Continuing Operating Activities		 -41 -28 -17 -15 -34 -18 -7.48 -13 -35 -9.67 -9.69
Net Income / (Loss) Continuing Operations		 -34 -29 -27 -26 -27 -24 -14 -16 -23 -11 -16
Consolidated Net Income / (Loss)		 -34 -29 -27 -26 -27 -24 -14 -16 -23 -11 -16
Depreciation Expense		 0.02 0.01 0.01 0.11 0.03 0.03 0.03 0.03 0.03 0.03 0.02
Amortization Expense		 -2.53 -2.21 -2.50 - - - - - - - -
Non-Cash Adjustments To Reconcile Net Income		 7.41 -4.72 10 12 4.13 0.61 1.70 2.60 1.03 -2.39 6.22
Changes in Operating Assets and Liabilities, net		 -12 8.80 1.54 -0.97 -11 5.15 4.92 0.60 -14 3.94 0.22
Net Cash From Investing Activities		 -273 -1.43 -71 -220 -0.07 -0.00 -0.05 -0.01 -0.03 -0.01 -0.02
Net Cash From Continuing Investing Activities		 -273 -1.43 -71 -220 -0.07 -0.00 -0.05 -0.01 -0.03 -0.01 -0.02
Purchase of Property, Plant & Equipment		 -0.85 -0.45 0.01 0.00 -0.07 -0.00 -0.05 -0.01 -0.03 -0.01 -0.02
Purchase of Investments		 -347 -73 -94 - - - - - - - -
Sale and/or Maturity of Investments		 75 72 - - - - - - - - -
Net Cash From Financing Activities		 244 29 0.43 173 16 7.76 0.46 154 77 149 0.02
Net Cash From Continuing Financing Activities		 244 29 0.43 173 16 7.76 0.46 154 77 149 0.02
Issuance of Common Equity		 234 - 0.03 173 15 -31 -0.16 181 49 54 -
Other Financing Activities, net		 9.96 1.20 0.40 0.57 0.81 38 0.62 -27 28 95 0.02
Cash Interest Paid		 0.70 - - - - - - - - - -
Cash Income Taxes Paid		 0.00 0.26 0.00 0.03 0.00 0.03 0.08 - 0.00 - -

Annual Balance Sheets for Gemini Therapeutics

This table presents Gemini Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Total Assets		 497 368 200 92 8.32
Total Current Assets		 494 366 198 90 5.07
Cash & Equivalents		 192 360 195 88 4.50
Short-Term Investments		 297 0.00 - - -
Prepaid Expenses		 3.73 5.28 3.88 2.45 0.56
Plant, Property, & Equipment, net		 0.75 0.17 0.17 0.11 0.29
Total Noncurrent Assets		 2.41 2.16 1.55 1.82 2.96
Other Noncurrent Operating Assets		 2.41 2.16 1.55 1.82 2.96
Total Liabilities & Shareholders' Equity		 497 368 200 92 8.32
Total Liabilities		 53 23 24 15 30
Total Current Liabilities		 23 21 23 13 25
Accounts Payable		 7.95 13 16 2.56 2.38
Accrued Expenses		 15 8.15 6.11 4.10 5.81
Other Current Liabilities		 0.13 0.67 0.31 6.77 -
Total Noncurrent Liabilities		 30 1.44 1.03 1.33 5.30
Long-Term Debt		 28 0.00 - - 4.95
Other Noncurrent Operating Liabilities		 1.55 1.44 1.03 1.33 0.35
Commitments & Contingencies		 0.00 0.00 0.00 0.00 -
Total Equity & Noncontrolling Interests		 444 345 177 78 -22
Total Preferred & Common Equity		 444 345 177 -64 -22
Preferred Stock		 0.00 0.00 - 142 0.00
Total Common Equity		 444 345 177 -64 -22
Common Stock		 741 534 289 1.19 91
Retained Earnings		 -298 -189 -112 -65 -113
Accumulated Other Comprehensive Income / (Loss)		 0.29 0.00 - - -

Quarterly Balance Sheets for Gemini Therapeutics

This table presents Gemini Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 709 495 510 354 376 384 244 106
Total Current Assets		 706 493 508 352 374 382 242 105
Cash & Equivalents		 123 193 281 343 371 378 236 102
Short-Term Investments		 572 295 220 - - - - -
Prepaid Expenses		 11 5.79 7.30 9.33 3.72 4.13 5.72 2.93
Plant, Property, & Equipment, net		 1.37 0.08 0.10 0.21 0.18 0.16 0.18 0.00
Total Noncurrent Assets		 2.30 1.91 1.88 2.02 2.05 2.28 1.46 1.37
Other Noncurrent Operating Assets		 2.30 1.91 1.88 2.02 2.05 2.28 1.46 1.37
Total Liabilities & Shareholders' Equity		 709 495 510 354 376 384 244 106
Total Liabilities		 49 27 21 16 18 13 11 1.46
Total Current Liabilities		 19 25 20 15 14 9.68 9.98 1.46
Accounts Payable		 6.70 3.55 4.75 5.27 8.50 5.21 5.64 1.14
Accrued Expenses		 12 22 15 8.82 5.57 4.15 4.03 0.33
Other Current Liabilities		 0.48 0.08 0.76 0.77 0.35 0.32 0.31 -
Total Noncurrent Liabilities		 30 1.71 1.08 1.26 3.11 3.27 0.95 0.00
Long-Term Debt		 29 - - - - - - 0.00
Other Noncurrent Operating Liabilities		 1.63 1.71 1.08 1.26 3.11 3.27 0.95 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -
Total Equity & Noncontrolling Interests		 660 468 489 338 359 371 233 105
Total Preferred & Common Equity		 660 468 489 338 359 371 233 105
Preferred Stock		 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 660 468 489 338 359 371 233 105
Common Stock		 992 736 731 554 524 522 368 315
Retained Earnings		 -332 -269 -242 -216 -165 -151 -135 -210
Accumulated Other Comprehensive Income / (Loss)		 0.54 0.74 -0.06 - - - - -

Annual Metrics And Ratios for Gemini Therapeutics

This table displays calculated financial ratios and metrics derived from Gemini Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -48.16% -91.85% -31.98% -6.60% 0.00%
EBIT Growth		 -42.35% -91.70% -32.11% -5.68% 0.00%
NOPAT Growth		 -42.35% -91.94% -53.48% 9.13% 0.00%
Net Income Growth		 -43.08% -63.22% -30.19% 11.92% 0.00%
EPS Growth		 -15.79% 92.41% -10.01% 11.92% 0.00%
Operating Cash Flow Growth		 -27.86% -73.87% -53.45% 15.82% 0.00%
Free Cash Flow Firm Growth		 -32.40% -159.87% -60.09% 0.00% 0.00%
Invested Capital Growth		 -17.76% 15.27% -73.47% -119.79% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -9.45% -22.29% -129.18% 40.87% 0.00%
EBIT Q/Q Growth		 -5.12% -22.26% -130.60% 41.08% 0.00%
NOPAT Q/Q Growth		 -3.87% -19.22% -291.48% 49.34% 0.00%
Net Income Q/Q Growth		 -5.68% -19.25% -167.49% 47.38% 0.00%
EPS Q/Q Growth		 -14.45% -29.55% -147.12% 47.38% 0.00%
Operating Cash Flow Q/Q Growth		 -11.62% -12.45% -222.81% 50.73% 0.00%
Free Cash Flow Firm Q/Q Growth		 -10.69% -70.15% -84.47% 0.00% 0.00%
Invested Capital Q/Q Growth		 7.38% -31.94% -736.43% -305.43% 0.00%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.33% 100.13% 100.00% 100.00% 100.00%
Interest Burden Percent		 84.03% 83.76% 98.51% 99.96% 119.94%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -27.73% -29.30% -36.84% -128.94% 186.80%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -27.73% -29.30% -16.28% 198.90% 186.80%
Return on Equity Simple (ROE_SIMPLE)		 -24.65% -22.15% -26.52% 56.02% 186.80%
Net Operating Profit after Tax (NOPAT)		 -91 -64 -33 -22 -24
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.51% -4.56% -9.62% -40.38% 99.25%
Return On Investment Capital (ROIC_SIMPLE)		 -19.24% -18.48% - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -130 -91 -48 -36 -34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -135 -91 -47 -36 -34
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 4.25 4.04 0.16 0.00 0.00
Price to Tangible Book Value (P/TBV)		 4.25 4.04 0.16 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.06 0.00 0.00 0.00 -0.99
Long-Term Debt to Equity		 0.06 0.00 0.00 0.00 -0.23
Financial Leverage		 -1.04 -1.06 -1.11 -1.27 -0.78
Leverage Ratio		 1.10 1.09 1.15 1.81 -0.38
Compound Leverage Factor		 0.92 0.91 1.13 1.80 -0.46
Debt to Total Capital		 6.00% 0.00% 0.00% 0.00% -9,791.86%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% -7,551.58%
Long-Term Debt to Total Capital		 6.00% 0.00% 0.00% 0.00% -2,240.27%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 182.68% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 94.00% 100.00% 100.00% -82.68% 9,891.86%
Debt to EBITDA		 -0.21 0.00 0.00 0.00 -0.64
Net Debt to EBITDA		 3.42 0.00 0.00 0.00 -0.51
Long-Term Debt to EBITDA		 -0.21 0.00 0.00 0.00 -0.15
Debt to NOPAT		 -0.31 0.00 0.00 0.00 -0.91
Net Debt to NOPAT		 5.08 0.00 0.00 0.00 -0.72
Long-Term Debt to NOPAT		 -0.31 0.00 0.00 0.00 -0.21
Altman Z-Score		 20.72 36.16 0.22 3.83 -31.95
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 55.79% 254.26% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 21.17 17.06 8.79 6.74 0.20
Quick Ratio		 21.01 16.81 8.62 6.56 0.18
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 -88 -67 -26 -16 0.00
Operating Cash Flow to CapEx		 -18,599.21% -82,541.57% -27,981.46% -40,491.18% -148,672.73%
Free Cash Flow to Firm to Interest Expense		 -154.01 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -164.21 0.00 0.00 0.00 -4.79
Operating Cash Flow Less CapEx to Interest Expense		 -165.09 0.00 0.00 0.00 -4.79
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -18 -15 -18 -10 -4.72
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.71 2.75 -7.63 -5.66 0.00
Enterprise Value (EV)		 1,425 1,034 -166 179 188
Market Capitalization		 1,887 1,394 29 125 171
Book Value per Share		 $14.91 $14.30 $4.08 ($1.49) ($1.41)
Tangible Book Value per Share		 $14.91 $14.30 $4.08 ($1.49) ($1.41)
Total Capital		 472 345 177 78 -0.22
Total Debt		 28 0.00 0.00 0.00 22
Total Long-Term Debt		 28 0.00 0.00 0.00 4.95
Net Debt		 -462 -360 -195 -88 17
Capital Expenditures (CapEx)		 0.51 0.09 0.15 0.07 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -20 -16 -19 -11 -7.63
Debt-free Net Working Capital (DFNWC)		 470 344 176 77 -3.12
Net Working Capital (NWC)		 470 344 176 77 -20
Net Nonoperating Expense (NNE)		 19 13 14 14 17
Net Nonoperating Obligations (NNO)		 -462 -360 -195 -88 17
Total Depreciation and Amortization (D&A)		 -5.15 0.10 0.09 0.03 0.32
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 ($3.96) ($3.42) ($45.05) ($53.40) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 27.61M 22.32M 1.04M 1.44M 0.00
Adjusted Diluted Earnings per Share		 ($3.96) ($3.42) ($45.05) ($53.40) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 27.61M 22.32M 1.04M 1.44M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($53.40) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 34.57M 24.68M 19.00M 1.35M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -91 -64 -33 -22 -24
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -226.78 0.00 0.00 0.00 -4.99
NOPAT to Interest Expense		 -158.75 0.00 0.00 0.00 -3.49
EBIT Less CapEx to Interest Expense		 -227.67 0.00 0.00 0.00 -4.99
NOPAT Less CapEx to Interest Expense		 -159.63 0.00 0.00 0.00 -3.49
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Gemini Therapeutics

This table displays calculated financial ratios and metrics derived from Gemini Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -35.05% -30.33% -86.74% -63.52% -25.25% -142.95% -15.40% -95.86% -155.03% -176.68% 10.87%
EBIT Growth		 -26.97% -22.41% -73.38% -63.89% -25.23% -142.64% -15.38% -95.67% -154.82% -176.08% 11.02%
NOPAT Growth		 -26.97% -16.28% -73.31% -78.05% -25.22% -97.82% -80.91% -44.22% -152.26% -151.73% 43.20%
Net Income Growth		 -26.48% -24.93% -88.35% -65.25% -18.30% -109.70% 12.56% -66.46% -131.21% -162.20% 12.94%
EPS Growth		 6.42% -0.94% -53.45% -39.19% 9.17% 90.20% 96.55% 92.70% 88.75% -152.58% 12.94%
Operating Cash Flow Growth		 -23.15% -54.94% -132.22% -20.98% 5.26% -84.13% 22.86% -38.39% -158.86% -149.57% 39.79%
Free Cash Flow Firm Growth		 -27.03% 8.81% -1,446.16% -245.19% -19.33% -715.80% 108.85% 59.93% -119.07% -111.11% -112.03%
Invested Capital Growth		 -27.00% -17.76% -67.74% -89.82% -27.39% 15.27% -508.73% -654.56% 1.38% -73.47% 210.50%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -15.52% -4.02% -14.88% 2.17% -11.48% -49.04% -0.60% 25.07% -116.25% 29.20% -70.73%
EBIT Q/Q Growth		 -15.63% -5.18% -6.42% 1.90% -11.48% -48.98% -0.59% 25.04% -116.00% 29.16% -70.59%
NOPAT Q/Q Growth		 -15.62% -5.16% -6.50% 1.94% -5.88% -56.74% -9.41% 31.03% -67.27% -43.34% 12.78%
Net Income Q/Q Growth		 -15.71% -10.74% -0.94% 2.22% -14.29% -66.97% 11.44% 30.00% -102.61% 30.38% -68.58%
EPS Q/Q Growth		 4.67% -20.22% 13.59% 5.50% -2.83% -82.76% 21.62% 38.33% 88.91% 35.67% -68.58%
Operating Cash Flow Q/Q Growth		 -50.06% -58.82% -12.79% 54.19% -88.80% -138.04% 41.24% 64.12% -266.95% 0.28% -5.42%
Free Cash Flow Firm Q/Q Growth		 -24.50% -41.62% 4.41% 24.63% 10.63% -2,190.71% 124.51% 73.94% -510.99% 77.32% -10.98%
Invested Capital Q/Q Growth		 67.89% 7.38% -60.14% -166.64% 70.22% -31.94% -81.22% -78.95% 80.20% -736.43% 145.87%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.35% 100.60% 100.43% 100.23% 100.02% 100.14% 100.14% 100.15% 100.10% 100.00% 100.00%
Interest Burden Percent		 85.02% 84.75% 80.63% 85.18% 85.64% 83.43% 74.44% 84.55% 90.58% 96.66% 98.36%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -23.34% -27.73% -25.03% -21.16% -28.23% -29.30% -27.65% -27.66% -34.69% -36.84% -14.27%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -490.46%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -23.34% -27.73% -25.03% -21.16% -28.23% -29.30% -27.65% -27.66% -34.69% -16.28% -14.27%
Return on Equity Simple (ROE_SIMPLE)		 -17.64% 0.00% -22.11% -18.62% -23.84% 0.00% -17.85% -17.81% -25.66% 0.00% -16.74%
Net Operating Profit after Tax (NOPAT)		 -28 -24 -23 -22 -22 -21 -13 -12 -18 -11 -7.34
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.21% -1.28% -0.84% -1.08% -1.70% -1.00% -0.36% -1.58% -2.95% -0.52% -7.19%
Return On Investment Capital (ROIC_SIMPLE)		 -4.06% -5.12% - - - -6.03% - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -40 -35 -33 -31 -31 -28 -19 -19 -25 -12 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -42 -37 -35 -31 -31 -28 -19 -19 -25 -12 -16
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.60 4.25 3.12 2.28 4.55 4.04 2.99 2.37 1.73 0.16 0.68
Price to Tangible Book Value (P/TBV)		 2.60 4.25 3.12 2.28 4.55 4.04 2.99 2.37 1.73 0.16 0.68
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.04 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.04 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.04 -1.04 -1.02 -1.01 -1.06 -1.02 -1.01 -1.02 -1.11 -1.00
Leverage Ratio		 1.07 1.10 1.05 1.04 1.05 1.09 1.04 1.04 1.07 1.15 1.07
Compound Leverage Factor		 0.91 0.93 0.85 0.89 0.90 0.91 0.77 0.88 0.97 1.11 1.05
Debt to Total Capital		 4.14% 6.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 4.14% 6.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 95.86% 94.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.20 -0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 4.57 3.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.20 -0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.29 -0.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 6.89 5.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.29 -0.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 21.37 21.35 32.39 31.54 57.22 36.72 37.17 41.16 22.14 0.81 26.95
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 55.79% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 37.65 21.17 19.36 25.02 23.70 17.06 25.96 39.42 24.26 8.79 71.49
Quick Ratio		 37.07 21.01 19.13 24.66 23.07 16.81 25.70 39.00 23.69 8.62 69.49
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -27 -21 -15 -16 -21 -24 1.13 -4.60 -18 -2.89 -13
Operating Cash Flow to CapEx		 -4,862.04% -6,140.98% 0.00% 0.00% -50,147.76% -593,200.00% -16,613.33% -106,033.33% -122,296.55% -80,541.67% -51,010.53%
Free Cash Flow to Firm to Interest Expense		 -29.81 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -46.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -47.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.77 -18 -19 -12 -4.54 -15 -12 -6.38 -3.57 -18 2.83
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.23 -2.71 -7.84 -5.73 -0.98 2.75 -14 -7.53 0.05 -7.63 5.39
Enterprise Value (EV)		 1,050 1,425 973 613 1,194 1,034 704 501 166 -166 -31
Market Capitalization		 1,716 1,887 1,461 1,114 1,537 1,394 1,075 879 403 29 71
Book Value per Share		 $19.10 $14.91 $15.74 $19.77 $13.70 $14.30 $15.69 $18.75 $5.37 $4.08 $2.42
Tangible Book Value per Share		 $19.10 $14.91 $15.74 $19.77 $13.70 $14.30 $15.69 $18.75 $5.37 $4.08 $2.42
Total Capital		 689 472 468 489 338 345 359 371 233 177 105
Total Debt		 29 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 29 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -666 -462 -487 -501 -343 -360 -371 -378 -236 -195 -102
Capital Expenditures (CapEx)		 0.85 0.45 -0.01 -0.00 0.07 0.00 0.05 0.01 0.03 0.01 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.80 -20 -20 -13 -5.52 -16 -11 -5.55 -4.26 -19 1.46
Debt-free Net Working Capital (DFNWC)		 687 470 468 488 337 344 360 372 232 176 103
Net Working Capital (NWC)		 687 470 468 488 337 344 360 372 232 176 103
Net Nonoperating Expense (NNE)		 6.12 5.27 3.60 4.76 4.93 2.78 0.85 3.82 5.19 0.73 8.81
Net Nonoperating Obligations (NNO)		 -666 -462 -487 -501 -343 -360 -371 -378 -236 -195 -102
Total Depreciation and Amortization (D&A)		 -2.51 -2.20 -2.49 0.11 0.03 0.03 0.03 0.03 0.03 0.03 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.02) ($1.07) ($0.89) ($1.03) ($1.09) ($1.06) ($0.58) ($0.74) ($1.20) ($10.82) ($2.40)
Adjusted Weighted Average Basic Shares Outstanding		 33.32M 27.61M 29.94M 25.65M 24.81M 22.32M 24.32M 21.48M 18.95M 1.04M 1.44M
Adjusted Diluted Earnings per Share		 ($1.02) ($1.07) ($0.89) ($1.03) ($1.09) ($1.06) ($0.58) ($0.74) ($1.20) ($10.82) ($2.40)
Adjusted Weighted Average Diluted Shares Outstanding		 33.32M 27.61M 29.94M 25.65M 24.81M 22.32M 24.32M 21.48M 18.95M 1.04M 1.44M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.07) $0.00 $0.00 $0.00 ($1.06) $0.00 $0.00 $0.00 ($10.82) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 34.63M 34.57M 29.76M 29.73M 24.72M 24.68M 24.14M 22.88M 19.80M 19.00M 1.44M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -24 -23 -22 -22 -21 -13 -12 -18 -11 -7.34
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -44.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -31.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -45.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -32.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Gemini Therapeutics' Financials

When does Gemini Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Gemini Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Gemini Therapeutics' net income changed over the last 4 years?

Gemini Therapeutics' net income appears to be on an upward trend, with a most recent value of -$109.36 million in 2024, rising from -$40.84 million in 2020. The previous period was -$76.43 million in 2023.

What is Gemini Therapeutics's operating income?
Gemini Therapeutics's total operating income in 2024 was -$129.72 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $129.72 million
How has Gemini Therapeutics revenue changed over the last 4 years?

Over the last 4 years, Gemini Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does Gemini Therapeutics have?

Gemini Therapeutics' total liabilities were at $53.19 million at the end of 2024, a 132.5% increase from 2023, and a 76.2% increase since 2020.

How much cash does Gemini Therapeutics have?

In the past 4 years, Gemini Therapeutics' cash and equivalents has ranged from $4.50 million in 2020 to $360.38 million in 2023, and is currently $192.43 million as of their latest financial filing in 2024.

How has Gemini Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, Gemini Therapeutics' book value per share changed from -1.41 in 2020 to 14.91 in 2024, a change of -1,159.3%.


Related Companies

This page (NASDAQ:GMTX) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored